Tyrosine kinase inhibitorFDA-approvedSecond-line
Lorbrena
Generic name: lorlatinib
How it works
Blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— ALK-positive
Efficacy
Studies show that lorlatinib can improve progression-free survival in patients with ALK-positive non-small cell lung cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Rare Lung Cancer Mutation Responds to New Treatment | Lung Cancer | lab-study | The patient achieved a durable partial response to lorlatinib (progression-free survival > 15 months). | Source → |
| Testing Lorlatinib and Ramucirumab in Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Long-term benefits of lorlatinib for lung cancer patients | Lung Cancer | phase-3 | 7-year PFS was 55% with lorlatinib and 3% with crizotinib. | Source → |
| Rare Lung Cancer Mutation Responds to Lorlatinib Treatment | Lung Cancer | observational | A partial response was achieved with lorlatinib as first-line therapy. | Source → |
| Evaluating Lorlatinib as a First-line Treatment for ALK-positive Lung Cancer in Chinese Adults | Lung Cancer | preclinical | — | Source → |
| Testing Lorlatinib with Local Consolidation Therapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining Lorlatinib and Envafolimab May Help Some Lung Cancer Patients | Lung Cancer | observational | The patient achieved a partial response after 4 months. | Source → |
| Lorlatinib Cost-Effective for Lung Cancer Patients in Italy | Lung Cancer | phase-3 | Lorlatinib provided higher benefits (+2.01 life-years; +1.66 quality-adjusted life-years) at lower costs (-€19,210 per patient) compared to alectinib. | Source → |
| Combining drugs to treat lung cancer with a specific genetic mutation | Lung Cancer | observational | — | Source → |
| Rare Side Effects Found in Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Lorlatinib Linked to Rare but Specific Neuropsychiatric Side Effects | Lung Cancer | observational | — | Source → |
| Lorlatinib Shows Promise in Lung Cancer Patients Who Have Tried Other Treatments | Lung Cancer | preclinical | The objective response rate was 42% (95% CI, 31%-55%). | Source → |
| Lorlatinib Efficacy and Safety in Lung Cancer Patients | Lung Cancer | observational | The objective response rate was 82.9% in the first-line treatment cohort, and the disease control rate was 100%. The median progression-free survival had not yet been reached in the first-line treatment cohort, and the median progression-free survival was 16.8 months in the subsequent-line treatment cohort. | Source → |
| Crushed Lorlatinib via Nasogastric Tube Helps Patient with Lung Cancer | Lung Cancer | observational | — | Source → |
| New Lung Cancer Treatments Show Promise but Raise Concerns | Lung Cancer | phase-3 | — | Source → |
| Lorlatinib Shows Promise in Lung Cancer Patients Who Failed Earlier Treatments | Lung Cancer | observational | The overall objective response rate was 64.6%, with the disease control rate of 96.3%. | Source → |
| Lorlatinib Linked to Higher Heart Risks in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Weight Gain Risk for Lung Cancer Patients on Lorlatinib | Lung Cancer | observational | Patients receiving lorlatinib experienced significantly higher maximum weight gain (mean 13.5% [95% confidence interval 10.8-16.2]) | Source → |
| Lorlatinib Monotherapy Shows Promise for Rare Lung Cancer | Lung Cancer | observational | — | Source → |
| Lorlatinib Therapy Linked to Unusual Lipid Levels | Lung Cancer | observational | — | Source → |
| Lorlatinib Shows Promise for Rare Lung Cancer | Lung Cancer | phase-1/2 | Median progression-free survival was 7.1 months [95% confidence interval (CI) 5.0-9.9 months] and overall survival from lorlatinib initiation was 19.6 months (95% CI 12.3-27.5 months). | Source → |
| Targeted Treatment Shows Promise in Pancreatic Cancer Patient | Pancreatic Cancer | observational | The patient achieved a durable stable disease with a progression-free survival of 12 months. | Source → |
| Lorlatinib Helps Patient with Advanced Lung Cancer | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.